Last updated on November 2019

Efficacy Safety and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis


Brief description of study

The primary objective of the study is to assess the efficacy of REGN3500 monotherapy in Atopic dermatitis (AD), as well as understand the dose-response relationship, compared with placebo treatment, in adult patients with moderate-to-severe AD.

Secondary objectives are to:

  • Assess the safety and tolerability of subcutaneous (SC) doses of REGN3500 monotherapy in adult patients with moderate-to-severe AD
  • Assess the Pharmacokinetics (PK) of REGN3500 in adult patients with moderate-to-severe AD
  • Assess the immunogenicity of REGN3500 in adult patients with moderate-to-severe AD

Clinical Study Identifier: NCT03738423

Find a site near you

Start Over

Regeneron Study Site

Ostrava, Czechia
0.91miles
  Connect »